Mount Sinai Uses Remote Patient Monitoring to Rapidly Respond to COVID-19

Newswise — A new remote monitoring platform developed by the Mount Sinai Health System is helping health care providers to care for COVID-19 patients who are recovering at home. With the platform, providers can monitor the patients’ symptoms and adjust care as necessary, including sending the patient to the hospital if symptoms worsen.

The platform was originally developed for stroke patients by Christopher Kellner, MD, and David Putrino, PhD, Co-Directors of Mount Sinai’s Precision Recovery Platform. When the COVID-19 outbreak began, Drs. Kellner and Putrino quickly repurposed it to address the large number of patients with confirmed or suspected COVID-19 whose symptoms are not severe enough to need hospitalization.

The COVID-19 version of the platform launched early last week and has already enrolled hundreds of patients.

“Technology has a massive role to play in this major health care crisis,” said Dr. Kellner, an Assistant Professor of Neurosurgery at the Icahn School of Medicine at Mount Sinai and Director of the Intracerebral Hemorrhage Program. “And with remote monitoring of COVID-19, we can save hospital resources for the patients who need them most, but also quickly triage patients if and when they begin to show more severe symptoms while they are being monitored at home.”

Dr. Putrino, an Assistant Professor of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai and Co-Director of the Abilities Research Center at Mount Sinai, said, “At the same time, we can also continue to provide vulnerable patients with excellent routine care, keep them out of the hospital, and shield them from additional exposure to the virus. We are saving lives.”

How Does It Work?

A patient can enroll in the program by a Mount Sinai Health System physician or the patient can text the words "Precision Recovery" to (332) 213-9130. A Mount Sinai provider from the Precision Recovery team will then contact them as soon as possible to establish an online video chat for on-boarding. As part of the on-boarding, the patient downloads a daily symptom tracking application, MyCap, which is completed via smart device to help the team track symptoms of the virus, such as body temperature, cough, breathing levels, and body aches. If a health care provider on the team sees concerning data during the home monitoring, the provider can enlist one of the Mount Sinai doctors on the team to have an online video chat with the patient. If necessary, they can organize an emergency medical team for mobilization. The program has escalated a handful of patients to the hospital so far. According to Drs. Kellner and Putrino, Precision Recovery has the capacity to help thousands more. To learn more about the program go to https://precisionrecovery.net/ 

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

 




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
1.89239